MedTrace Logo

A Phase II, Multicenter, Double Blind, Placebo-Controlled Safety, Tolerability Study of BMS-708163 in Patients With Mild to Moderate Alzheimer's Disease

NCT00810147 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 209

Last updated 2015-10-12

No results posted yet for this study

Summary

The purpose of this study is to determine the safety and tolerability of BMS-708163 in patients with mild to moderate Alzheimer's disease over a treatment period of 12-weeks and the course of any potential effects during a 12-week wash-out period

Conditions

Interventions

DRUG

BMS-708163

Capsules, Oral, 25 mg, once daily, 24 weeks

DRUG

BMS-708163

Capsules, Oral, 50 mg, once daily, 24 weeks

DRUG

BMS-708163

Capsules, Oral, 100 mg, once daily, 24 weeks

DRUG

BMS-708163

Capsules, Oral, 125 mg, once daily, 24 weeks

DRUG

Placebo

Capsules, Oral, 0 mg, once daily, 24 weeks

Sponsors & Collaborators

Principal Investigators

  • Bristol-Myers Squibb · Bristol-Myers Squibb

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
50 Years
Max Age
90 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-02-28
Primary Completion
2010-06-30
Completion
2010-06-30

Countries

  • United States
  • Denmark
  • Finland
  • Sweden

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00810147 on ClinicalTrials.gov